Steering Committee Actions Sample Clauses

Steering Committee Actions. Actions to be taken by the Steering Committee pursuant to the terms of this Agreement shall be taken only following the unanimous vote of the members of the Steering Committee. The Steering Committee shall attempt to have all decisions approved by all members of the Steering Committee. If the members of the Steering Committee cannot reach a unanimous decision with respect to items (a) through (e) above or matters referred to it for approval within sixty (60) days following such referral, then, subject to Section 16.01 hereof, the final decision on such matters shall be made by Schering; PROVIDED, HOWEVER, that prior to the implementation of such decision the Chief Executive Officer of Alliance shall be given the opportunity to meet and consult with the head of Schering's Strategic Business Unit "Diagnostics" in a timely manner.
Sample 1Sample 2
AutoNDA by SimpleDocs
Steering Committee Actions. (a) Limitations of Powers of the Steering Committee. The Steering Committee shall have only such powers as are specifically delegated to it hereunder. The Steering Committee is not a substitute for the rights of He Parties and is intended for coordination of the research and development of Product(s) during the Term.
Sample 1Sample 2
Steering Committee Actions. Actions to be taken by the -------------------------- Steering Committee pursuant to the terms of this Agreement shall be taken only following the unanimous vote of the members of the Steering Committee. The Steering Committee shall attempt to have all decisions approved by all members of the Steering Committee. If the members of the Steering Committee cannot reach a unanimous decision with respect to Development matters related to a Development Indication referred to it for approval within sixty (60) days following such referral, the final decision on such matters shall be made by CTI, except for Excepted Development Matters. If the Steering Committee cannot reach a unanimous decision with respect to Development matters related to an Additional Indication referred to it for approval within sixty (60) days following such referral, the final decision in such matters shall be made by ORTHO, except for Excepted Development Matters. If the members of the Steering Committee cannot reach a unanimous decision with respect to any of the Excepted Development Matters which have been referred to it pursuant to Section 4.02(b) for resolution or approval by the JDC, the status quo shall be maintained with respect to Excepted Development Matters items (i) and (ii) in Section 4.02(b). As to Excepted Development Matter item (iii) in Section 4.02(b), the clinical trial shall be terminated if the Steering Committee does not reach another decision after prompt consideration. If the members of the Steering Committee cannot reach a unanimous decision with respect to a Commercialization matter referred to it for approval within sixty (60) days following such referral, the final decision on such matter shall be made by ORTHO, except for Excepted Commercialization Matters as provided in Section 7.01(b). Except as provided for above in this Section 2.04, if the Steering Committee fails to reach agreement on a matter before it for decision, the matter shall be referred to executive officers of the Parties pursuant to Section 16.01. The manner described in this Section 2.04 to resolve disputes regarding Excepted Development matters and Excepted Commercialization Matters shall be the sole mechanism for resolving such Matters under this Agreement. If either CTI or ORTHO wishes to seek a nonbinding opinion from a Third Party with respect to any issue before the Steering Committee for decision, it may do so at its own expense; provided, however, that if both Parties agree to seek such -...
Sample 1Sample 2
Steering Committee Actions. No business will be transacted at any meeting of the Steering Committee unless at least one member from each Party is present. Actions by the Steering Committee will be taken only with the unanimous approval of members of the Steering Committee. If the Steering Committee is unable to reach unanimity on any matter within fifteen (15) days of the first vote at which no unanimous decision was reached on such matter, then either Party may move that the Chief Executive Officers (or a member of the senior management designated by the Chief Executive Officer who is not a member of the Steering Committee) meet and seek to resolve the matter in good faith within fifteen (15) days of referral in accordance with Section 21 below. If such discussions should not result in a mutually acceptable resolution within fifteen (15) days of such meeting, then either Party may initiate Arbitration procedures pursuant to Section 21 below.
Sample 1
Steering Committee Actions. Actions to be taken by the -------------------------- Steering Committee pursuant to the terms of this Agreement shall be taken only following the unanimous vote of the members of the Steering Committee. The Steering Committee shall attempt to have all decisions approved by all members of the Steering Committee. If the members of the Steering Committee cannot reach a unanimous decision with respect to Development matters referred to it for approval within sixty (60) days following such referral, the final decision on such matters shall be made by ORTHO
Sample 1
Steering Committee Actions 
Sample 1

Related to Steering Committee Actions

  • Steering Committee Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Operating Committee 7.01 To coordinate the operation of their respective generating, transmission and substation facilities, in order that the advantages to be derived hereunder may be realized by the parties hereto to the fullest practicable extent, the parties shall establish a committee of authorized representatives to be known as the Operating Committee. Each of the parties shall designate in writing delivered to the other party, the person who is to act as its representative on said committee (and the person or persons who may serve as alternates whenever such representative is unable to act). Each of such representatives and alternates shall be persons familiar with the generating, transmission, and substation facilities of the system of the party he represents, and each shall be fully authorized (1) to cooperate with the other representative (or alternates) and (2) to determine and agree from time to time, in accordance with this agreement and with any other relevant agreements then in effect between the parties, upon the following:

  • Joint Remediation Committee If the Sellers (acting reasonably) determine that the Purchasers have committed a Major Default, then, at the election of the Sellers, within three (3) Business Days of the Sellers providing the Purchasers written notice of such determination, the Sellers and the Purchasers shall establish a joint remediation committee of designated executives from the Sellers and the Purchasers (“Joint Remediation Committee”) consisting of three (3) members of each of the Sellers and the Purchasers. The Joint Remediation Committee shall be responsible for overseeing the development of a mutually agreeable plan in accordance with subsection 3 below to either (i) remediate any breaches giving rise to the Major Default to the extent such breaches can be remediated and/or (ii) prevent similar breaches from recurring in the future (clauses (i) and (ii), a “Corrective Action Plan”). Each member of the Joint Remediation Committee shall have sufficient authority on the part of his or her respective party to make decisions relating to matters reviewed by the Joint Remediation Committee, and shall be approved by the other party (such approval not to be unreasonably delayed, conditioned or withheld). The Joint Remediation Committee shall have access to Purchaser Personnel that are primarily responsible for the area of the business relationship (such as information technology, data security or regulatory) where the breaches giving rise to the Major Default arise (such Purchaser Personnel, collectively, the “Subject Matter Experts”). The Sellers and the Purchasers shall cause their respective members on the Joint Remediation Committee to, and the Purchasers shall cause the Subject Matter Experts to, act in good faith in connection with the development of the Corrective Action Plan.

  • Transition Committee Prior to the Effective Time, the Parties shall establish a transition committee (the “Transition Committee”) that shall consist of an equal number of members designated by Baxter and Baxalta at all times, with each Party having the right to replace the Transition Committee members delegated by it from time to time and taking such efforts as are necessary from time to time to cause the Transition Committee to consist of an equal number of representatives of Baxter and Baxalta (in a total number determined from time to time by the Parties). The Transition Committee shall be responsible for monitoring and managing all matters related to any of the transactions contemplated by this Agreement or any Ancillary Agreements. The Transition Committee shall have the authority to (a) establish one or more subcommittees from time to time as it deems appropriate or as may be described in any Ancillary Agreements, with each such subcommittee comprised of an equal number of members representing each Party, and each such subcommittee having such scope of responsibility as may be determined by the Transition Committee from time to time; (b) delegate to any such committee any of the powers of the Transition Committee; and (c) to combine, modify the scope of responsibility of, and disband any such subcommittees, and to modify or reverse any such delegations. The Transition Committee shall establish general procedures for managing the responsibilities delegated to it under this Section 2.14, and may modify such procedures from time to time. All decisions by the Transition Committee or any subcommittee thereof shall be effective only with majority approval, and any such approval must include the approval of at least one member of the Transition Committee designated by Baxter and at least one member of the Transition Committee designated by Baxalta. The Parties shall utilize the procedures set forth in Article VII to resolve any matters as to which the Transition Committee is not able to reach a decision.

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Research Committee 2.2.1 Establishment and Functions of the RC. -------------------------------------

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!